HER2 Support Group Forums - View Single Post - a new kind of her2neu +er= breast cancer type--baso-luminal!

Lani · 07-22-2006, 10:21 AM

with an even shorter disease-free and overall survival than triple-negative!

1: Clin Cancer Res. 2006 Jul 15;12(14):4185-91. Links
Basoluminal carcinoma: a new biologically and prognostically distinct entity between Basal and luminal breast cancer.

Laakso M,
Tanner M,
Nilsson J,
Wiklund T,
Erikstein B,
Kellokumpu-Lehtinen P,
Malmstrom P,
Wilking N,
Bergh J,
Isola J.
Authors' Affiliations: Department of Pathology, Seinajoki Central Hospital, Seinajoki, Finland.
PURPOSE: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that is typically hormone receptor negative and shows a distinct gene expression profile. Based on variable basal cytokeratin immunostaining patterns, we hypothesized that the "basal phenotype" tumor group may comprise more than one biological entity. EXPERIMENTAL DESIGN: Basal cytokeratins 5 and 14 (CK5/14) were stained by immunohistochemistry and the percentage of positive cells was defined by image analysis. The results thus obtained were compared with clinicopathologic characteristics and relapse-free survival. RESULTS: Of the 506 breast tumors, 53 (10.5%) showed immunoreactivity for CK5/14. Basal cytokeratin expression showed up as two microscopically distinguishable subtypes, i.e., a uniformly positive type ("basal") and a partially positive type ("basoluminal") often displaying a checkerboard-type intratumoral heterogeneity. These subgroups could also be separated with a third basal cytokeratin (CK17, P < 0.0001). Both basal and basoluminal subtypes were hormone receptor negative and of high grade, but differed with respect to the Ki-67 labeling index (P = 0.0014), vimentin (P = 0.005), and c-kit (P = 0.02), which were more frequently expressed in basal than in basoluminal tumors. In contrast, the amplification of HER-2 was found almost exclusively in the basoluminal subgroup (P = 0.009). Compared with the basal tumors, basoluminal tumors associated with significantly shorter relapse-free survival (P = 0.01), which was not explained by their more frequent HER-2 amplification. CONCLUSIONS: We conclude that the intratumoral heterogeneity in basal cytokeratin expression can be used to define two distinct breast cancer subtypes, basal and basoluminal, with distinctive features related to proliferation activity, oncogene and biomarker status, and patient survival.
PMID: 16857790 [PubMed - in process]

The more they look, the more subtypes they find. Hopefully they will delineate markers for targetted therapies of each type.

07-22-2006, 10:21 AM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	a new kind of her2neu +er= breast cancer type--baso-luminal! with an even shorter disease-free and overall survival than triple-negative! 1: Clin Cancer Res. 2006 Jul 15;12(14):4185-91. Links Basoluminal carcinoma: a new biologically and prognostically distinct entity between Basal and luminal breast cancer. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Bergh J, Isola J. Authors' Affiliations: Department of Pathology, Seinajoki Central Hospital, Seinajoki, Finland. PURPOSE: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that is typically hormone receptor negative and shows a distinct gene expression profile. Based on variable basal cytokeratin immunostaining patterns, we hypothesized that the "basal phenotype" tumor group may comprise more than one biological entity. EXPERIMENTAL DESIGN: Basal cytokeratins 5 and 14 (CK5/14) were stained by immunohistochemistry and the percentage of positive cells was defined by image analysis. The results thus obtained were compared with clinicopathologic characteristics and relapse-free survival. RESULTS: Of the 506 breast tumors, 53 (10.5%) showed immunoreactivity for CK5/14. Basal cytokeratin expression showed up as two microscopically distinguishable subtypes, i.e., a uniformly positive type ("basal") and a partially positive type ("basoluminal") often displaying a checkerboard-type intratumoral heterogeneity. These subgroups could also be separated with a third basal cytokeratin (CK17, P < 0.0001). Both basal and basoluminal subtypes were hormone receptor negative and of high grade, but differed with respect to the Ki-67 labeling index (P = 0.0014), vimentin (P = 0.005), and c-kit (P = 0.02), which were more frequently expressed in basal than in basoluminal tumors. In contrast, the amplification of HER-2 was found almost exclusively in the basoluminal subgroup (P = 0.009). Compared with the basal tumors, basoluminal tumors associated with significantly shorter relapse-free survival (P = 0.01), which was not explained by their more frequent HER-2 amplification. CONCLUSIONS: We conclude that the intratumoral heterogeneity in basal cytokeratin expression can be used to define two distinct breast cancer subtypes, basal and basoluminal, with distinctive features related to proliferation activity, oncogene and biomarker status, and patient survival. PMID: 16857790 [PubMed - in process] The more they look, the more subtypes they find. Hopefully they will delineate markers for targetted therapies of each type.